Mural Oncology (NASDAQ:MURA) Now Covered by HC Wainwright

Equities research analysts at HC Wainwright initiated coverage on shares of Mural Oncology (NASDAQ:MURA) in a report released on Thursday, Benzinga reports. The firm set a “buy” rating and a $18.00 price target on the stock. HC Wainwright’s price target suggests a potential upside of 383.87% from the stock’s previous close.

MURA has been the subject of several other reports. Rodman & Renshaw began coverage on shares of Mural Oncology in a research note on Friday, June 28th. They issued a “buy” rating and a $15.00 target price for the company. Raymond James assumed coverage on Mural Oncology in a report on Friday, October 4th. They set a “strong-buy” rating and a $18.00 price target for the company.

Mural Oncology Trading Up 7.8 %

Shares of MURA stock opened at $3.72 on Thursday. The firm’s 50 day moving average is $3.26 and its 200-day moving average is $3.45. Mural Oncology has a 1 year low of $2.88 and a 1 year high of $17.00. The firm has a market capitalization of $62.96 million and a price-to-earnings ratio of -0.36.

Mural Oncology (NASDAQ:MURA) last posted its earnings results on Tuesday, August 13th. The company reported ($1.86) earnings per share for the quarter, topping the consensus estimate of ($1.90) by $0.04. On average, equities research analysts forecast that Mural Oncology will post -7.47 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Mural Oncology

Large investors have recently modified their holdings of the company. BBR Partners LLC bought a new position in Mural Oncology in the 2nd quarter valued at about $31,000. Rhumbline Advisers bought a new position in shares of Mural Oncology in the second quarter valued at approximately $34,000. Canada Pension Plan Investment Board bought a new position in shares of Mural Oncology in the second quarter valued at approximately $70,000. Dimensional Fund Advisors LP purchased a new position in shares of Mural Oncology during the second quarter valued at approximately $71,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in Mural Oncology during the second quarter worth $84,000. 80.21% of the stock is currently owned by institutional investors.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.